Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Sequenom Announces Launch of SensiGene Fetal RHD Genotyping Test
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Sequenom, Inc. has announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's first laboratory developed test powered by its SEQureDx™ technology.
In the United States, there are approximately 528,000 pregnancies in Rhesus D (RhD) negative women every year, and almost all of these women could benefit from an assessment of the RhD type of the fetus. RhD type can be determined by an invasive procedure, such as amniocentesis or chorionic villus sampling (CVS), but both procedures involve risk to the fetus. Currently in the United States, most RhD negative women are managed without knowing the fetal RHD status.
The benefits of the noninvasive SensiGene Fetal RHD Genotyping test include:
• Aid to physicians in creating a more informed strategy to manage the care of pregnant RhD negative women.
• Reduction in need for invasive procedures, such as amniocentesis or CVS.
• First trimester detection.
• Fetal identifiers - a control to confirm the presence of fetal DNA thus ensuring that a RHD negative result for a female fetus is due to the measurement of fetal rather than maternal nucleic acid in the sample.
"The introduction of this test is an important development in improving patient care for pregnant women in both the United States and in Europe," said Dr. Wolfgang Holzgreve, director at the University Hospital, Freiburg and Sequenom clinical advisory board member.
In the United States, there are approximately 528,000 pregnancies in Rhesus D (RhD) negative women every year, and almost all of these women could benefit from an assessment of the RhD type of the fetus. RhD type can be determined by an invasive procedure, such as amniocentesis or chorionic villus sampling (CVS), but both procedures involve risk to the fetus. Currently in the United States, most RhD negative women are managed without knowing the fetal RHD status.
The benefits of the noninvasive SensiGene Fetal RHD Genotyping test include:
• Aid to physicians in creating a more informed strategy to manage the care of pregnant RhD negative women.
• Reduction in need for invasive procedures, such as amniocentesis or CVS.
• First trimester detection.
• Fetal identifiers - a control to confirm the presence of fetal DNA thus ensuring that a RHD negative result for a female fetus is due to the measurement of fetal rather than maternal nucleic acid in the sample.
"The introduction of this test is an important development in improving patient care for pregnant women in both the United States and in Europe," said Dr. Wolfgang Holzgreve, director at the University Hospital, Freiburg and Sequenom clinical advisory board member.
